Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CDCP1

CDCP1

Basics

Aliases:
This biomarker is also known as:
  • transmembrane and associated with src kinases,
  • CD318,
  • subtractive immunization M plus HEp3-associated 135 kDa protein,
  • TRASK,
  • CUB domain-containing protein 1,
  • Membrane glycoprotein gp140,
  • SIMA135,
  • Transmembrane and associated with src kinases,
  • CD318 antigen,
  • CUB domain containing protein 1,
  • membrane glycoprotein gp140,
  • Q9H5V8,
  • Subtractive immunization M plus HEp3-associated 135 kDa protein,

View in BioMuta

Description…

CDCP1 is a transmembrane protein containing three extracellular CUB domains. It is found to be overexpressed in colon and lung cancers. Its expression level is correlated with the metastatic ability of carcinoma cells. CDCP1 is located on the cell surface and may be involved in cell adhesion and cell matrix association. Alternatively spliced transcript variants encoding distinct isoforms have been reported.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CDCP1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

CDCP1 is a transmembrane tumor vascular marker (TVM) that is selectively expressed in tumor vasculature and represents a promising target for vascular imaging or anti-vascular therapy of epithelial ovarian cancer.

Performance Comment

CDCP1 was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of CDCP1 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.